Literature DB >> 7847322

Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenia purpura.

J W Taub1, I Warrier, C Holtkamp, D S Beardsley, J M Lusher.   

Abstract

The majority of children with idiopathic thrombocytopenia (ITP) have an acute self-limiting course and no diagnostic test has been identified which will predict the course of thrombocytopenia and detect those with the chronic autoimmune form. The detection of autoantibodies directed against the platelet glycoprotein complex IIB/IIIa, may identify patients with chronic ITP. Serum anti-GP IIb/IIIa antibodies were assessed by the indirect MAIPA assay in 54 children with immune thrompocytopenia at initial presentation along with an additional 7 children previously diagnosed with chronic ITP, to determine if there was a difference in antibody positivity between acute and chronic ITP patients, and whether the identification of antibodies could be used as a predictive test at diagnosis. There was no significant difference in the percentage of antibodies detected in children classified with acute ITP (27/40-68%) compared to children with chronic ITP (13/21-62%, P > 0.05). Patients with acute ITP had significantly lower mean platelet counts at diagnosis compared to the chronic ITP group (16,225/mm3 vs 32,250/mm3, P < 0.05), though there was no significant difference in the bleeding manifestations between the acute and chronic ITP groups. Serum anti-GP IIb/IIIa antibodies are detected in a high percentage of children with ITP and autoantibodies appear to be involved in the pathogenesis of both acute and chronic ITP. The detection of anti-GP IIb/IIIa antibodies at diagnosis, however, does not appear to be a useful prognostic test in childhood ITP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7847322     DOI: 10.1002/ajh.2830480207

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  Laboratory investigation of immune thrombocytopenia.

Authors:  M Warner; J G Kelton
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

Review 2.  Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms.

Authors:  Priscilla H Wong; Kevin M White
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 3.  Idiopathic thrombocytopenic purpura.

Authors:  P H Bolton-Maggs
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

Review 4.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  The thrombocytopenic purpuras. Recognition and management.

Authors:  S Gillis
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

6.  Severe Immune Thrombocytopenia Complicated by Intracerebral Haemorrhage Associated with Coronavirus Infection: A Case Report and Literature Review.

Authors:  Mohamed Magdi; Ali Rahil
Journal:  Eur J Case Rep Intern Med       Date:  2019-07-12

7.  Diagnosis and management of coronavirus disease-associated immune thrombocytopenia: a case series.

Authors:  Fatma Yılmaz Aydın; Vehbi Demircan
Journal:  Rev Soc Bras Med Trop       Date:  2021-04-28       Impact factor: 1.581

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.